Dispepsia: caracterização e abordagem

Silva, Fernando Marcuz

doi:10.11606/issn.1679-9836.v87i4p213-223

Cited by 10 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Functional dyspepsia is characterized by a set of chronic and recurrent symptoms that are usually located in the epigastric region, in the absence of structural or metabolic and biochemical abnormali ties that justify the symptomatology (9,13,20) . Dyspeptic symptoms may appear at any age and are more preva lent in females (8) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test

Costa

Azeredo

Marciano

et al. 2012

Arq. Gastroenterol.

View full text Add to dashboard Cite

Context Functional dyspepsia is a condition in which symptoms are not related to organic underlying disease; its patho genesis is not well known. The small intestinal bacterial overgrowth (SIBO) is characterized by the increase in the number and/or type of colonic bacteria in the upper gastrointestinal tract. The hypothesis of SIBO being associated to functional dyspepsia must be considered, since the impaired motility of the gastrointestinal tract is one of the main etiologic factors involved on both pathologies. Objective To determine if there is SIBO in patients with functional dyspepsia. Methods Case control study, evaluating 34 patients: 23 functional dyspeptic and 11 non dyspeptic (control group). Questionnaire applied based on Rome III criteria. The patients un derwent H 2 lactulose breath test, considered positive when: H 2 peak exceeding 20 ppm, in relation to fasting, or two peaks exceeding 10 ppm sustained until 60 minutes. Results Of the 23 dyspeptic patients, 13 (56.5%) obtained positive results for SIBO trough the H 2 lactulose breath test. On control group, SIBO was not observed. The association between the dyspeptic group and the control group regarding SIBO was statistically significant, with P = 0.0052. In the group of dyspeptic patients, 12 (52.2%) were using proton pump inhibitor; of these 9 (75%) were positive for SIBO. In the control group, none of the 11 patients used proton pump inhibitors and SIBO was not observed. The association of the dyspeptic group using proton pump inhibitor that were positive for SIBO and the control group was statistically significant, with P = 0.0011. Conclusion It was found that, patients with functional dyspepsia presented SIBO, when they underwent to H2 lactulose breath test, compared to the non dyspeptic. In addition, it was observed a higher prevalence of SIBO in dyspeptic patients that were using proton pump inhibitors, compared to control group.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Although a benign condition, its patho genesis is not well defined (20) . It is the most common reason for medical consultations, both for general and specialists, and it may affect up to 25% of popu lation (7) .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test

Costa

Azeredo

Marciano

et al. 2012

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The use of omeprazole may be justified by gastroesophageal reflux disease or dyspepsia, depending on whether or not the patient has stress daily or poor dietary habits. Thus, these factors could be solved with better diet habits or even through an improved lifestyle 17,18 .…”

Section: Discussionmentioning

confidence: 99%

Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions

Correia

Costa

Rocha

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Currently, dyspeptic syndrome or functional dyspepsia is characterized as a common universal problem presenting several disorders, especially peptic diseases determined by chloridropeptic dysfunction; these include gastroesophageal reflux disease and gastroduodenal peptic ulcer. Although occurring with less intensity, infection with H. pylori is directly linked to the development of this pathology, with a significant reduction or complete elimination observed when the patient is subjected to treatment with drugs to combat the bacterium [26][27][28].…”

Section: Major Pathologies Associated With the Presence Of Helicobactmentioning

confidence: 99%

Antimicrobial activity of natural products against Helicobacter pylori : a review

Bonifácio

Ramos

Silva

et al. 2014

Annals of Clinical Microbiology and Antimicrobials

View full text Add to dashboard Cite

Throughout the genetic and physiological evolution of microorganisms, the microbiological sciences have been expanding the introduction of new therapeutic trials against microbial diseases. Special attention has been paid to the bacterium Helicobacter pylori, which induces gastric infections capable of causing damage, ranging from acute and chronic gastritis to the development of gastric cancer and death. The use of compounds with natural origins has gained popularity in scientific research focused on drug innovation against H. pylori because of their broad flexibility and low toxicity. The aim of this study was to describe the use of natural products against H. pylori in order to clarify important parameters for related fields. The study demonstrated the vast therapeutic possibilities for compounds originating from natural sources and revealed the need for innovations from future investigations to expand the therapeutic arsenal in the fight against H. pylori infection.

show abstract

Dispepsia: caracterização e abordagem

Cited by 10 publications

References 20 publications

Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test

Evaluation of small intestine bacterial overgrowth in patients with functional dyspepsia through H2 breath test

Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions

Antimicrobial activity of natural products against Helicobacter pylori : a review

Contact Info

Product

Resources

About